학술논문
First-Line Nivolumab Plus Ipilimumab in Advanced NSCLC: 4-Year Outcomes From the Randomized, Open-Label, Phase 3 CheckMate 227 Part 1 Trial
Document Type
Article
Author
Paz-Ares, Luis G.; Ramalingam, Suresh S.; Ciuleanu, Tudor-Eliade; Lee, Jong-Seok; Urban, Laszlo; Caro, Reyes Bernabe; Park, Keunchil; Sakai, Hiroshi; Ohe, Yuichiro; Nishio, Makoto; Audigier-Valette, Clarisse; Burgers, Jacobus A.; Pluzanski, Adam; Sangha, Randeep; Gallardo, Carlos; Takeda, Masayuki; Linardou, Helena; Lupinacci, Lorena; Lee, Ki Hyeong; Caserta, Claudia; Provencio, Mariano; Carcereny, Enric; Otterson, Gregory A.; Schenker, Michael; Zurawski, Bogdan; Alexandru, Aurelia; Vergnenegre, Alain; Raimbourg, Judith; Feeney, Kynan; Kim, Sang-We; Borghaei, Hossein; O'Byrne, Kenneth John; Hellmann, Matthew D.; Memaj, Arteid; Nathan, Faith Ellen; Bushong, Judith; Tran, Phuong; Brahmer, Julie R.; Reck, Martin
Source
In Journal of Thoracic Oncology February 2022 17(2):289-308
Subject
Language
ISSN
1556-0864